Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: AMG 714 for Vitiligo
NCT04338581Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ordesekimab in Vitiligo, sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2020; status: completed.
02
Drugs
ordesekimab
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT04338581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338581.